Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
The independent monitoring committee advised that the trial was unlikely to meet its overall survival endpoint.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) announced its decision to discontinue the Phase 3 IMpactMF trial of imetelstat in relapsed or refractory myelofibrosis. The independent Data Monitoring Committee recommended stopping because the trial was unlikely to meet its primary endpoint of overall survival. No new safety signals were observed that change imetelstat’s known safety profile or require additional safety monitoring.
The trial evaluated 327 patients with intermediate-2 or high-risk disease after JAK inhibitor treatment. Patients were randomized 2:1 to imetelstat or best available therapy in an open-label trial, meaning treatment assignments were known. Geron plans a detailed data analysis and will share findings with the scientific community at a future date. The company remains committed to growing U.S. RYTELO demand and broadening access for eligible lower-risk myelodysplastic syndrome patients outside the U.S.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointNo new safety signals changed imetelstat’s known safety profile or required additional safety monitoring.
- Minor point. Forward-looking: it has not happened yet and may not happen.RYTELO commercial plans remain focused on growing U.S. demand and broadening eligible patient access outside the U.S.
Negative
- Major pointPhase 3 IMpactMF discontinuation follows the independent committee’s assessment that the overall survival endpoint was unlikely to be met.
Details
Market move: GERN -6.96% vs previous close. Phase 3 trial discontinuation
On Oct 28, the day this news came out, the latest delayed price for GERN is 6.96% below the previous close. Argus tracked a trough of -14.8% from its starting point during tracking. Our momentum scanner has recorded 13 alerts for this stock so far that day. The latest delayed price is $1.07. Relative volume is exceptionally heavy at 596.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Trial phase
- Phase 3
- IMpactMF trial
- Patients evaluated
- 327 patients
- Relapsed or refractory myelofibrosis after a JAK inhibitor
- Randomization
- 2:1
- Imetelstat versus best available therapy
- Imetelstat dose
- 9.4 mg/kg IV every three weeks
- IMpactMF imetelstat arm
Key Terms
data monitoring committee medical
overall survival medical
jak inhibitor medical
open label technical
relapsed/refractory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Committee (DMC).
The independent DMC advised Geron that the trial was unlikely to meet its primary endpoint of overall survival. There were no new safety signals observed in the trial that change the known safety profile of imetelstat or require additional safety monitoring. A detailed analysis of the data will be conducted, and study findings will be shared with the scientific community at a future date.
“Given the recommendation from the DMC, we believe discontinuing our Phase3 IMpactMF trial at this time is the right course of action. We are deeply grateful to the patients and families, as well as the investigators and clinical teams whose dedication made this research possible,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “Hematologic malignancies are complex diseases, with distinct biological characteristics and treatment challenges across patient populations. We remain committed to thoroughly evaluating the data, understanding what we can learn, and sharing insights that may help inform future research and address the significant unmet needs that remain.”
IMpactMF evaluated 327 patients with intermediate-2 or high-risk myelofibrosis who were relapsed or refractory to a JAK inhibitor. Patients were randomized 2:1, in an open label, controlled trial of imetelstat designed to evaluate a potential improvement in overall survival compared to best available therapy. Patients in the imetelstat arm received 9.4 mg/kg IV every three weeks.
“As we fully analyze the data from the IMpactMF trial, we remain committed to growing RYTELO demand in the U.S. and broadening access to eligible LR-MDS patients outside the U.S.,” said Harout Semerjian, President and Chief Executive Officer of Geron. “We have a growing commercial business, a strong financial foundation, and a clear strategy to pursue innovation to create long-term value and build a leading hematology company.”
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) Geron’s plans to discontinue the Phase 3 IMpactMF trial; (ii) the ongoing analysis of IMpactMF data and the timing and plans for sharing study findings with the scientific community; (iii) the potential for insights from these analyses to inform future research; (iv) Geron’s plans and efforts to grow RYTELO demand in the United States and expand access for eligible patients; (v) Geron’s strategy and ability to create long-term value and build a leading hematology company; and (vi) other statements that are not historical facts. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including risks and uncertainties relating to: (a) the timing, costs and execution of discontinuing IMpactMF; (b) whether further analyses of IMpactMF data yield additional or different findings, including regarding efficacy and safety, and the timing and extent of disclosure of those findings; (c) whether insights from clinical data translate into future research or clinical benefits; (d) the impact of the IMpactMF results and discontinuation on Geron’s development plans, business and financial condition; (e) Geron’s ability to grow RYTELO demand, achieve market acceptance and expand patient access in the United States, including risks relating to competition, coverage and reimbursement; (f) regulatory requirements and actions affecting imetelstat’s development and commercialization; (g) failures or delays in manufacturing or supplying sufficient quantities of RYTELO or clinical trial materials; and (h) Geron’s ability to execute its strategy and maintain sufficient financial resources to support its business. Additional information regarding these and other risks and uncertainties is contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying them may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why is Geron discontinuing the Phase 3 IMpactMF trial?
Geron decided to discontinue IMpactMF after the independent Data Monitoring Committee advised that it was unlikely to meet its primary endpoint of overall survival. The trial compared imetelstat with best available therapy in patients with myelofibrosis that had relapsed after, or was refractory to, a JAK inhibitor.